January 2014
THE POLIO ERADICATION ENDGAME
BRIEF ON IPV INTRODUCTION, OPV WITHDRAWAL AND ROUTINE IMMUNIZATION STRENGTHENING
The Polio Eradication and Endgame Strategic Plan 2013-2018 was drawn up in response to the May 2012 World Health Assembly declaring the completion of poliovirus eradication to be a programmatic emergency for global public health.
Under this endgame plan to achieve and sustain a polio-free world, the use of oral polio vaccine (OPV) must eventually be stopped worldwide, starting with OPV that contains type 2 poliovirus (OPV type 2). At least one dose of inactivated polio vaccine (IPV) must be introduced as a risk mitigation measure.
The steps involved are:
1. By end 2015, introduce at least 1 dose of IPV into all routine immunization systems, at least 6 months before the switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV, containing types 1 and 3 poliovirus).
2. During 2016, switch from tOPV to bOPV, which does not contain type 2 virus, in routine immunization and polio campaigns.
3. Plan for the eventual withdrawal of all OPV.
The tOPV to bOPV switch is necessary because:
No wild poliovirus type 2 has been recorded over the past years and the risk of paralytic polio disease due to the type 2 component of OPV now outweighs its benefits.
Since OPV is a live attenuated vaccine, in rare cases it can cause paralytic disease in two ways: as Vaccine Associated Paralytic Poliomyelitis (VAPP) or in outbreaks of circulating Vaccine-Derived Poliovirus (cVDPV). The vast majority of cVDPV outbreaks and a substantial proportion of the total VAPP cases are due to the type 2 component of OPV.
Replacing tOPV with bOPV is key to ensuring the eradication of type 2 poliovirus.
The switch from tOPV to bOPV will serve as a ‘dry run’ for the withdrawal of the other types of OPV.
IPV needs to be introduced on an accelerated timeline so that OPV type 2 can be withdrawn.
IPV should be introduced at least 6 months before the switch from tOPV to bOPV, i.e., by the end of 2015. Countries using only OPV in their routine immunization programmes should be prepared for a switch from tOPV to bOPV in 2016.
1. RI Task Force Meeting
20th January 2015
Update of AIA
2. Accelerated Immunization Activity :Objectives
• To increase the immunization coverage with all vaccines under the
National Immunization Schedule.
• To reach the beneficiaries in hard to reach areas, especially those who
are left out from routine services.
4. Accelerated Immunization Activity :Target population
• Category A (Highest priority): Areas which are never or rarely reached e.g.
• Not reachable during harsh winter (Seasonal problems),
• Sub centers without vaccinator having >10 clients /day,
• villages with poor access,
• Urban slums, periurban areas,
• Villages with poor access,
• Vacant sub-centers,
• Migrant and mobile populations,
• Marginalized population etc.
• Category B (Second priority): Areas where immunization was planned but
not held during previous 3-4 months.
• Category C (Third priority): Villages/urban areas where RI is normally done
but coverage is considered low.
6. Provinces-17 out of total 34 Round 1 Round 2 Round 3
Farah, Nuristan, Helmand, Uruapan, Kandahar, Ghor, Kabul, Badghis, Faryab,
Daikundi, Logar, Ghazni, Khost, Badakhshan, Kunzar Sari-Pul, Wardak.
11th to 16th October 2014 22 to 27th November 2014 27th December to 1st January 2015
15. Action points
• Letter to concerned PEMTs to conduct remaining rounds before end
of Feb 2015.
• Collection of the reports from the remaining provinces
• Monitoring plan from NEPI and partners
• Regularize Quarterly accelerated catch up rounds:
( based on the coverage and other criteria to make microplans to cover
the left outs and dropouts from each district)
16. Inclusion of age group of 5 to 9 years for the
planned measles campaign in 2015
17.
18. 5
14
8 9 12 13
1
0
2
1 1
9 7
20
11
9 17
3
8
2
16
17
15
29
27
28
7
2
1
0
2
15
11
29
47
19
44
16
24
17
6
7
11
11
19
13
2
1
1
2
2 9
9
16 13
11
18
15
4
5
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Nov-13 Dec-13 Jan-14 Feb-14 Mar-14 Apr-14 May-14 Jun-14 Jul-14 Aug-14
Monthly distribution of Measles cases by age category in Afghanistan January 2013-AUG
2014
<1 Year 1-4 Years 5-9 Years 10-14 Years 15-19 Years 20-24 Years 25+ Years
23. 0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Percentofpopulation
Age (in years)
Protected by maternal antibodies Protected by routine vaccination with 1st dose
Protected by routine vaccination with 2nd dose Protected by SIAs
Unprotected by vaccination
Current Immunity
gap :Measles 2014
24. 0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Percentofpopulation
Age (in years)
Protected by maternal antibodies Protected by routine vaccination with 1st dose
Protected by routine vaccination with 2nd dose Protected by SIAs
Unprotected by vaccination
Reduction of Immunity
gapo with 9 Months to 5
years.
25. 0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Percentofpopulation
Age (in years)
Protected by maternal antibodies Protected by routine vaccination with 1st dose
Protected by routine vaccination with 2nd dose Protected by SIAs
Unprotected by vaccination
Reduction of Immunity gap
with 9 Months to 9 years.
26. Action points
• Explore funding options for inclusion of 5-9 years for the upcoming
measles campaign
• Planning for 9months to 9 years
• Preparation steps to including of cold chain management and space
for the huge campaign